ClinicalTrials.gg
Active, not recruitingNCT07512271Updated Nov 12, 2026

Generative AI Patient Education Module for Breast Oncology

An interventional study of Survey (Participant) and OpenEvidence CareConnect in Breast Cancer, Metastatic Breast Cancer and Carcinoma of the Breast, sponsored by University of California, San Francisco. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Health services research

How we know

Updated Nov 12, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Planned enrollment
26th of 49
35 · median 38
Started
2026
with 3 others
No phase
23 of 62
4 open now
Primary completion
2027-01
later than 1 of 15 live
Registered
60th of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 1 of the 15 other live ones, and was the 60th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate sites.

Read the detailed description

PRIMARY OBJECTIVES:

I. Lead-in period: To evaluate the safety of the OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool during the initial lead-in phase in patients with metastatic breast cancer.

II. To evaluate the clinical accuracy and appropriateness of the OpenEvidence CareConnect RAG LLM tool in delivering general health and breast cancer-specific information.

SECONDARY OBJECTIVES:

I. To assess patient perceptions of the AI tool's helpfulness, alignment with other information sources, and its impact on communication with their oncology care team.

II. To evaluate provider perceptions of the tool's usefulness and impact on communication and the quality of patient education.

III. To compare patient experiences and perceptions between immediate access and delayed access to the AI educational tool.

EXPLORATORY OBJECTIVES:

I. To evaluate the changes in inter-visit communication between patient and care team with and without access to the AI tool.

II. To understand patient concerns and educational needs related to breast cancer diagnosis and treatment.

OUTLINE: The first 5 participants will be assigned to the Lead-In Phase. After which, the next 30 participants will be randomized to either an Intervention arm or a Waitlist Control arm. Participants on the Waitlist Control arm will cross over after 3 months to the Intervention arm. Surveys and provider assessments occur throughout, and adherence and safety are monitored during the lead-in. Each participant will be on study for approximately 6 months.

03

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer
  • Carcinoma of the Breast

Browse trials for

Keywords

  • Artificial Intelligence (AI)
  • Digital Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females or males ages 18 and over.
  2. Patients must have either:

    1. Stage IV breast cancer facing a treatment change and are expected to have follow-up visits at least once every three months, or
    2. Stage I-III breast cancer diagnosed within the past 6 months.
  3. Basic computer literacy and regular internet access at home.
  4. Able to understand study procedures and to comply with them for the entire length of the study.
  5. Ability of individual or legal guardian/representative to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. to any study-related procedure or assessment.
  2. Cognitive impairment that would interfere with tool usage or survey completion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Safety Lead-in Phase

    Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.

    Other: Survey (Participant) · Other: OpenEvidence CareConnect · Other: Survey (Provider)

  • Experimental
    Interventional (Immediate Access)

    Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.

    Other: Survey (Participant) · Other: OpenEvidence CareConnect · Other: Survey (Provider)

  • Experimental
    Control (Delayed Access)

    Participants will be given access to OpenEvidence CareConnect for 3 months 90 days after enrollment

    Other: Survey (Participant) · Other: OpenEvidence CareConnect · Other: Survey (Provider)

Interventions

  • OtherSurvey (Participant)

    Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.

  • OtherOpenEvidence CareConnect

    Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool

  • OtherSurvey (Provider)

    The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.

06

What researchers measure

Primary outcomes

  1. Mean score of Safety and Risk Assessment (Lead-in and Provider)

    Safety and Risk Assessment evaluates safety concerns based on provider responses using a 5-point Likert scale.

    Time frame: Up to 90 months

  2. Mean score of Provider Assessment of AI patient Education Tool Survey (Provider)

    AI patient Education Tool Survey evaluates clinical accuracy and appropriateness of the OpenEvidence CareConnect tool based on provider responses using a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree).

    Time frame: Up to 180 days

  3. Mean score of Assessment of Answer Accuracy and Content Appropriateness (Provider)

    Provider will evaluate participant questions, answer accuracy and content provided within the OpenEvidence using 3-point scales.

    Time frame: Uup to 180 days

Secondary outcomes

  1. Mean score of AI Tool Experience survey (Participant)

    The AI Tool Experience Survey is a 40-question instrument to assess participants' perceptions of usability, usefulness, clinical integration, and support for shared decision-making. Each item is rated on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree).

    Time frame: Up to 180 days

  2. Mean score of Medical Information Experience Survey (Participant)

    Medical Information Experience Survey is a 13-question instrument to evaluate how participants access and engage with medical information. Questions are measured using a 5-point Likert scale.

    Time frame: up to 180 days

  3. Mean Change of Score of Patient AI Tool Experience Survey (Participant)

    The AI Tool Experience Survey is a 40-question instrument to assess participants' perceptions of usability, usefulness, clinical integration, and support for shared decision-making. Each item is rated on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Comparisons of survey responses between the immediate and delayed access groups will be reported.

    Time frame: up to 180 days

  4. Mean Change of Score of Medical Information Experience Survey (Participant)

    Medical Information Experience Survey is a 13-question instrument evaluates how participants access and engage with medical information. Questions are measured using a 5-point Likert scale. Comparisons of survey responses between the immediate and delayed access groups will be reported.

    Time frame: Up to 180 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 6 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Jul 14, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07512271
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Jul 14, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Michelle Melisko, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion